Teva Pharmaceuticals (Switzerland)

Recent papers from Teva Pharmaceuticals (Switzerland)

1. Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington DiseaseNeurology and Therapy · 2024
2. Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension StudyMovement Disorders Clinical Practice · 2023
3. A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimodBrain Communications · 2023
4. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension StudyCNS Drugs · 2022
5. Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazineParkinsonism & Related Disorders · 2022
6. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyFrontiers in Neurology · 2022
7. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette SyndromeJAMA Network Open · 2021
8. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette SyndromeJAMA Network Open · 2021
9. Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive DyskinesiaCNS Spectrums · 2021
10. Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy VolunteersClinical and Translational Science · 2020
11. Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor DevicesDigital Biomarkers · 2019
12. Characterizing patient compliance over six months in remote digital trials of Parkinson’s and Huntington diseaseBMC Medical Informatics and Decision Making · 2018
13. Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjectsBritish Journal of Clinical Pharmacology · 2018
14. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaClinical Cancer Research · 2016
15. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary ReportJournal of Aerosol Medicine and Pulmonary Drug Delivery · 2010